Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Metabolic syndrome linked to higher risk of Parkinson’s disease August 20, 2025 Beer consumption alters red blood cell lipid composition October 21, 2024 Study links obstructive sleep apnea to increased dementia risk in women November 1, 2024